On September 5, 2026, clinical oncology teams and patient advocacy networks reaffirmed Zejula® (Niraparib 100 mg film-coated tablets) as a cornerstone targeted maintenance therapy for adult patients battling advanced ovarian, fallopian tube, and primary peritoneal cancers. As an orally active, highly potent poly (ADP-ribose) polymerase (PARP) inhibitor developed by GlaxoSmithKline (GSK), Zejula provides substantial progression-free survival (PFS) extension following response to platinum-based chemotherapy regimens.

Through Critical Kare Pharma, certified original GlaxoSmithKline packs of Zejula Niraparib 100mg Tablets 56's are made accessible to oncology hospitals, prescribing physicians, and named patients globally via GDP-certified cold-chain export, validated Certificate of Analysis (COA) batch release, and international personal importation pathways.

Key Clinical Pharmacology & Mechanism of Action

Zejula (niraparib) operates through selective inhibition of both PARP-1 and PARP-2 enzymes. These nuclear proteins are essential for repairing single-strand breaks in cellular DNA via the base excision repair (BER) pathway:

• PARP Enzyme Trapping: Niraparib traps PARP-1 and PARP-2 enzymes at sites of DNA damage, preventing normal enzyme release and blocking DNA replication forks.
• Synthetic Lethality: In cancer cells with homologous recombination deficiency (HRD)—such as those harboring BRCA1 or BRCA2 mutations or non-BRCA genomic instability—the inability to repair resulting double-strand DNA breaks causes catastrophic genomic instability and selective tumor cell apoptosis, leaving non-cancerous repair-competent cells viable.
• Broad Response Profile: Unlike earlier generation targeted agents, pivotal Phase 3 trials (such as the PRIMA and NOVA studies) demonstrated clinically meaningful PFS improvements across both HRD-positive and HRD-proficient/biomarker-negative patient cohorts in first-line and platinum-sensitive recurrent maintenance settings.

Individualized Starting Dose (ISD) Protocol

To optimize clinical efficacy while significantly mitigating high-grade hematologic adverse reactions (notably thrombocytopenia and neutropenia), modern oncologic guidelines mandate an Individualized Starting Dose (ISD) based on baseline patient weight and platelet parameters:

• Baseline Body Weight ≥ 77 kg AND Platelet Count ≥ 150,000/μL: Recommended starting dose is 300 mg once daily (three 100 mg tablets taken orally at bedtime).
• Baseline Body Weight < 77 kg OR Platelet Count < 150,000/μL: Recommended starting dose is 200 mg once daily (two 100 mg tablets taken orally at bedtime).
• Administration Guidelines: Film-coated tablets must be swallowed whole with water, with or without food. Bedtime dosing is frequently recommended by clinicians to alleviate potential early nausea or gastrointestinal discomfort.

Laboratory Monitoring & Safety Standards

Patient safety protocols require rigorous baseline and periodic clinical monitoring during Zejula therapy:

• Complete Blood Count (CBC): Weekly monitoring for the first month of therapy, monthly for the remaining first year, and periodically thereafter to guide dose modifications, treatment interruptions, or reductions if required.
• Cardiovascular Metrics: Monthly blood pressure and heart rate evaluations, especially during the initial three months of treatment.
• Prescription Storage: Store in original carton at room temperature below 30°C (86°F), protected from excessive heat and direct moisture.

Global Named-Patient Sourcing via Critical Kare Pharma

For international patients facing domestic supply chain shortages, protracted national formulary delays, or prohibitive retail markups, Critical Kare Pharma facilitates direct, fully compliant cross-border procurement of genuine GlaxoSmithKline Zejula 100 mg (56 compresse rivestite con film):

• Regulatory Authorization: Coordinated under official personal import programs including US FDA Personal Importation Policy (PIP), UK MHRA Named-Patient Import, Australian TGA Special Access Scheme (SAS), ANVISA RDC exemptions, and Saudi SFDA personal clearance frameworks.
• Authenticity Verification: Every unit is sourced strictly through licensed European and UK pharmaceutical distributors, accompanied by manufacturer batch testing reports, tamper-evident security seals, and verifiable Certificates of Analysis (COA).
• Rapid Climate-Secure Transit: Express courier dispatch with real-time temperature tracking and delivery directly to specialized cancer centers, hospital pharmacies, or registered residential addresses within 4 to 8 business days worldwide.

Inquire with our clinical oncology desk for batch availability, pricing inquiries, and country-specific customs documentation support: support@Critical Kare Pharma.com or speak directly with our oncology pharmacists via WhatsApp (+91 94275 19809).